Johannes F. Fahrmann, Ph.D.
Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences
Education & Training
Degree-Granting Education
| 2013 | Marshall University, Huntington, WV, USA, PHD, Biomedical Sciences, Cancer Biology |
| 2009 | Marshall University, Huntington, WV, USA, BS, Biological Sciences |
| 2009 | Marshall University, Huntington, WV, USA, BS, Chemistry |
Experience & Service
Academic Appointments
Instructor, Department of Clinical Cancer Prevention - Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2020
Postdoctoral Fellow, Department of Clinical Cancer Prevention - Research, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2015 - 2017
Graduate Student, Biomedical Sciences, Marshall University, Huntington, WV, 2009 - 2013
Grant & Contract Support
| Date: | 2024 - 2026 |
| Title: | Microbiome translation of peptidoglycan biosynthesis pathway for CAR-T therapy |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-Investigator |
| Date: | 2024 - 2029 |
| Title: | Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| Date: | 2024 - 2026 |
| Title: | Development of probiotics to augment CAR-T therapeutic responses |
| Funding Source: | Gabrielle Angel Foundation |
| Role: | Co-Investigator |
| ID: | N/A |
| Date: | 2023 - 2027 |
| Title: | Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer |
| Funding Source: | NCI |
| Role: | Principal Investigator |
| ID: | 1U01CA282216-01 |
| Date: | 2023 - 2028 |
| Title: | Targeting Non-Canonical STING Signaling to Treat SPOP Mutant Castration-Resistant Prostate Cancer |
| Funding Source: | NIH |
| Role: | Co-Investigator |
| ID: | R01 CA281727 |
| Date: | 2023 - 2028 |
| Title: | Repurposing glucosylceramide synthase to promote mitochondrial lethality and potentiate an anti-tumor immune response in triple-negative breast cancer |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator |
| ID: | 1R01CA269611-01A1 |
| Date: | 2022 - 2027 |
| Title: | Clinical Validation Center for Early Detection of Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| ID: | U01CA200468 |
| Date: | 2022 - 2024 |
| Title: | Coffee and Caffeine Metabolites and Disease Progression in Men Enrolled on Active Surveillance for Prostate Cancer |
| Funding Source: | American Institute for Cancer Research (AICR) |
| Role: | Co-Investigator |
| ID: | N/A |
| Date: | 2021 - 2026 |
| Title: | Longitudinal Proteomic and Metabolomic Predictors of Pancreatic Cyst Malignant Progression and Early-Stage Pancreatic Cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| ID: | U01CA239522 |
| Date: | 2021 - 2023 |
| Title: | Molecular Characterization of Interval Breast Cancers |
| Funding Source: | Komen |
| Role: | Co-Investigator |
| ID: | SAC160064 |
| Date: | 2020 - 2021 |
| Title: | Validation of a MYC-driven polyamine signature for detection of ovarian cancer |
| Funding Source: | MD Anderson SPORE in Ovarian Cancer Career Enhancement Program Award |
| Role: | CEP PI |
| ID: | P50 CA217685 |
| Date: | 2020 - 2021 |
| Title: | Pancreatic Moon Shot, Flagship 3, Early Detection of Pancreatic Cancer, |
| Funding Source: | The University of Texas MD Anderson Cancer Center |
| Role: | Co-Investigator |
| ID: | 4U24CA224020-02 |
| Date: | 2020 - 2026 |
| Title: | The potential risks and benefits of electronic cigarettes to older smokers at high risk for lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| ID: | R01 CA238478 |
| Date: | 2020 - 2022 |
| Title: | Identifying Actionable Signatures of Duodenopancreatic Neuroendocrine Tumor Progression in MEN1 |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| ID: | R21 CA252426-01 |
| Date: | 2019 - 2021 |
| Title: | McKee Early Career Investigator in Pancreatic Cancer Research |
| Funding Source: | UT MD Anderson Cancer Center Moon Shots |
| Role: | Principal Investigator |
| Date: | 2019 - 2020 |
| Title: | Pancreatic Moon Shot, Flagship 2, Early Detection of Pancreatic Cancer |
| Funding Source: | The University of Texas MD Anderson Cancer Center, Moon Shots |
| Role: | Co-Investigator |
| Date: | 2019 - 2021 |
| Title: | The role of KYNU upregulation in lung adenocarcinoma |
| Funding Source: | American Lung Association |
| Role: | Co-Investigator |
| ID: | AWD00004530 |
| Date: | 2019 - 2021 |
| Title: | A Biomarker Bakeoff in Early Stage Pancreatic Cancer |
| Funding Source: | UTMDACC Set Aside Funds |
| Role: | Co-Investigator |
| ID: | FP00010164 |
| Date: | 2018 - 2019 |
| Title: | Lipidomics-based biomarkers for risk of progression in early prostate cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| ID: | 1R21CA223527-01 |
| Date: | 2017 - 2021 |
| Title: | Intercepting Pancreatic Cancer in High Risk Cohorts |
| Funding Source: | American Association for Cancer Research (AACR) |
| Role: | Co-Investigator |
| ID: | SU2C-AACR-DT25-17 |
| Date: | 2017 - 2019 |
| Title: | Assessment of the application of metabolomics for lung cancer risk assessment and early detection |
| Funding Source: | MD Anderson Cancer Center, Duncan Family Institute for Cancer Prevention and Risk Assessment |
| Role: | Principal Investigator |
| Date: | 2016 - 2021 |
| Title: | Intercepting Pancreatic Cancer in High Risk Cohorts |
| Funding Source: | NIH/NCI |
| Role: | Co-Investigator |
| ID: | 1U01CA200468 |
Patient Reviews
CV information above last modified January 25, 2024